

University of Louisville Dermatology Spring Meeting 5/17/2019

This activity was created to address the professional practice gaps listed below:

- Recognizing skin disease in pediatric patients.
- Managing patients with therapies that are based on the highest level of evidence.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [16-3.94]	(0)	(0)	(1) 6.25%	(15) 93.75%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [15-3.87]	(0)	(0)	(2) 13.33%	(13) 86.67%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [16-3.81]	(0)	(1) 6.25%	(1) 6.25%	(14) 87.50%

2. Please elaborate on your previous answers. (5)

excellent meeting

Rare conditions

I now understand the associations with PTEN gene mutation.

great

Very interesting cases and quality presentations.

3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Jeffrey P. Callen, MD [16-3.88]	(0)	(0)	(2) 12.50%	(14) 87.50%
Megha Tollefson, MD [16-3.94]	(0)	(0)	(1) 6.25%	(15) 93.75%

4. Please elaborate on your previous answers. (3)

Dr. Tollefson gave practical talks on infantile hemangiomas, overgrowth syndromes, capillary malformations, and treatment of pediatric atopic dermatitis and pediatric psoriasis.

great

Both physicians were well prepared and knowledgeable.

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (8)

None

Consider topical sirolimus

Different monitoring and treatment of certain vascular conditions

I will evaluate child with forehead capillary malformation for Sturge Weber Syndrome. appropriate referrals for propranolol therapy.

I will not be managing some of the more complex cases but it is always good to know the next step and what patients can expect.

6. How certain are you that you will implement this change? (8)

Very Certain ⁽³⁻
37.50%)

Not Certain ⁽³⁻
37.50%)

Certain ⁽²⁻
25.00%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (2)

peds

cutaneous manifestations of systemic disease

8. Were the patient recommendations based on acceptable practices in medicine? (12)

Yes ⁽¹²⁻
100.00%)

10. Do you think the presentation was without commercial bias? (12)

Yes ⁽¹²⁻
100.00%)

12. Please provide any additional comments you may have about this educational activity. (3)

I prefer to have live patients as opposed to virtual patients. I feel like I learn a lot more and remember it better when I see the patients in person.

great

I enjoy the live patient viewing.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



University of Louisville Dermatology Spring Meeting Outcomes

1. Please rate the following aspects of this activity.

(1=Strongly Disagree, 2=Disagree, 3=Agree, 4-Strongly Agree)

	Strongly Disagree			Strongly Agree
Attending this activity improved my competence. [6-3.50]	(1) 16.67%	(0)	(0)	(5) 83.33%
Attending this activity improved my performance. [6-3.50]	(1) 16.67%	(0)	(0)	(5) 83.33%
What I learned from this activity has helped me improve my patient outcomes. [6-3.50]	(1) 16.67%	(0)	(0)	(5) 83.33%

2. If this activity improved your competence, please tell us how. (2)

Better recognize pediatric dermatology cases related to social media pressures.

Evaluation and work up to start propranolol for infantile hemangiomas

3. If this activity improved your performance, please tell us how. (2)

Review and update current knowledge.

Better recognition of the paradoxical eruption from anti-TNFs in pediatric patients.

4. Discuss how your Patient Outcomes (omit patient names) have improved as a result of attending this activity. (1)

Improved treatment of morphea and expected duration of therapy.

5. Identify practice changes you have made as a result of attending this activity. (2)

improved differential diagnosis

See above

6. What topics do you want to hear more about, and what issue(s) in your practice will this help address? (2)

pediatric dermatology. complex medical dermatology subjects

Any pediatric derm is great.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.